Clinical toxicities of nanocarrier systems

被引：246

作者：

Vega-Villa, Karina R. ^{[1
,2
]}

Takemoto, Jody K. ^{[1
,2
]}

Yanez, Jaime A. ^{[1
,2
]}

Remsberg, Connie M. ^{[1
,2
]}

Forrest, M. Laird ^{[3
]}

Davies, Neal M. ^{[1
,2
]}

机构：

[1] Washington State Univ, Coll Pharm, Pharmacol & Toxicol Grad Program, Pullman, WA 99164 USA

[2] Washington State Univ, Coll Pharm, Dept Pharmaceut Sci, Pullman, WA 99164 USA

[3] Univ Kansas, Dept Pharmaceut Chem, Coll Pharm, Simon Labs, Lawrence, KS 66047 USA

来源：

ADVANCED DRUG DELIVERY REVIEWS | 2008年 / 60卷 / 08期

关键词：

nanoparticle; toxicity; nanomedicine; nanocarrier; polymeric micelles; dendrimer; nanosphere; nanopharmaceutics;

D O I：

10.1016/j.addr.2007.11.007

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Toxicity of nanocarrier systems involves physiological, physicochemical, and molecular considerations. Nanoparticle exposures through the skin, the respiratory tract, the gastrointestinal tract and the lymphatics have been described. Nanocarrier systems may induce cytotoxicity and/or genotoxicity, whereas their antigenicity is still not well understood. Nanocarrier may alter the physicochemical properties of xenobiotics resulting in pharmaceutical changes in stability, solubility, and pharmacokinetic disposition. In particular, nanocarriers may reduce toxicity of hydrophobic cancer drugs that are solubilized. Nano regulation is still undergoing major changes to encompass environmental, health, and safety issues. The rapid commercialization of nanotechnology requires thoughtful environmental, health and safety research, meaningful, and an open discussion of broader societal impacts, and urgent toxicological oversight action. (C) 2008 Elsevier B.V. All rights reserved.

引用

页码：929 / 938

页数：10

共 82 条

[1]

Aliabadi Hamidreza Montazeri, 2006, Expert Opin Drug Deliv, V3, P139

[2] Polymeric micelles for the solubilization and delivery of cyclosporine A: pharmacokinetics and biodistribution [J].

Aliabadi, HM ;

Brocks, DR ;

Lavasanifar, A .

BIOMATERIALS, 2005, 26 (35) :7251-7259

[3] Liposomal drug formulations - Rationale for development and what we can expect for the future [J].

Allen, TM .

DRUGS, 1998, 56 (05) :747-756

[4] Treatment with liposome-encapsulated clodronate as a new strategic approach in the management of immune thrombocytopenic purpura in a mouse model [J].

Alves-Rosa, F ;

Stanganelli, C ;

Cabrera, J ;

van Rooijen, N ;

Palermo, MS ;

Isturiz, MA .

BLOOD, 2000, 96 (08) :2834-2840

[5] Solution structures and integrin binding activities of an RGD peptide with two isomers [J].

Assa-Munt, N ;

Jia, X ;

Laakkonen, P ;

Ruoslahti, E .

BIOCHEMISTRY, 2001, 40 (08) :2373-2378

[6] Topical non-invasive gene delivery using gemini nanoparticles in interferon-γ-deficient mice [J].

Badea, Ildiko ;

Wettig, Shawn ;

Verrall, Ronald ;

Foldvari, Marianna .

EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2007, 65 (03) :414-422

[7] Liposome application: problems and prospects [J].

Barenholz, Y .

CURRENT OPINION IN COLLOID & INTERFACE SCIENCE, 2001, 6 (01) :66-77

[8] Combustion-derived nanoparticles:: Mechanisms of pulmonary toxicity [J].

BeruBe, Kelly ;

Balharry, Dominique ;

Sexton, Keith ;

Koshy, Lata ;

Jones, Tim .

CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2007, 34 (10) :1044-1050

[9] Is nanotechnology ready for primetime? [J].

Brower, V .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2006, 98 (01) :9-11

[10] Nanomedicine: An unresolved regulatory issue [J].

Chan, Vivian S. W. .

REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2006, 46 (03) :218-224

← 1 2 3 4 5 6 7 8 9 →